Cambridge Healthtech Institute’s 6th Annual

Rational Combination Cancer Immunotherapy

Data Drives Combinatorial Strategies and Successes

August 27-28, 2018

As the discovery of new cancer immunotherapies continues to grow, developers are identifying promising patient-specific neoantigens and finding new ways to modulate the immune response beyond or in combination with checkpoint inhibitors. Numerous clinical studies are exploring the application of these therapeutics in combinations with traditional and experimental agents. Thus, emerging data from these preclinical models and clinical trials demonstrate the need for massive data analytics to provide actionable answers for patients. CHI’s 6th Annual Rational Combination Cancer Immunotherapy conference takes a forward-looking perspective on the design of drug products and treatment progressions and builds on the knowledge arising from these exploratory trials.

Preliminary Agenda

KEYNOTE PRESENTATION: Rational Combination of Immunotherapy, It Is Science, Not Logic

Samir Khleif, MD, Immunotherapy Scientist, Jeannie and Tony Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University


Forward and Reverse Translational Approaches to Augment Response to Anti-PD1 Therapy

Sarah Javaid, PhD, Associate Principal Scientist, Genetics and Pharmacogenomics, Merck

Leveraging Systems Biology and Machine Learning to Improve IO Biomarkers and Inform Combination Therapies

Janusz Dutkowski, PhD, CEO, Data4Cure, Inc.

Leveraging Clinical and Preclinical Targeted Therapy Biomarker Data to Inform Combinations with Immunotherapy

Matthew Meyer, PhD, Senior Investigator II, Oncology Pharmacology, Novartis Institutes for BioMedical Research, Inc.


Multiple “Immune Defects” in Pancreatic Cancer: How Do We Find the Right Combination of Immunotherapy?

Lei Zheng, MD, PhD, Associate Professor, Oncology and Surgery, Gastrointestinal Cancer Program, Tumor Immunology Program/Bloomberg-Kimmel Institute for Cancer Immunotherapy (BKI), The Pancreatic Cancer Precision Medicine Program, Graduate Program in Cellular & Molecular Medicine, The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Graduate Program in Molecular and Cellular Medicine, Johns Hopkins University School of Medicine

Hypomethylating Agents in Combination with Immune Checkpoint Inhibitors in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Naval Daver, MD, Associate Professor, Leukemia Department, MD Anderson Cancer Center


Translational Immuno-Oncology in the Age of Big Data – A Bioinformatics Perspective

Yuriy Gusev, PhD, Associate Professor, Innovation Center for Biomedical Informatics (ICBI), Georgetown University

A Dynamic View of Cancer Dynamics and Drug Resistance

Doron Levy, PhD, Professor, Department of Mathematics, University of Maryland

For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286